These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34514745)

  • 1. Scientific and regulatory evaluation of empirical pharmacometric models: An application of the risk informed credibility assessment framework.
    Skottheim Rusten I; Musuamba FT
    CPT Pharmacometrics Syst Pharmacol; 2021 Nov; 10(11):1281-1296. PubMed ID: 34514745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consideration of a Credibility Assessment Framework in Model-Informed Drug Development: Potential Application to Physiologically-Based Pharmacokinetic Modeling and Simulation.
    Kuemmel C; Yang Y; Zhang X; Florian J; Zhu H; Tegenge M; Huang SM; Wang Y; Morrison T; Zineh I
    CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):21-28. PubMed ID: 31652029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using forest plots to interpret covariate effects in pharmacometric models.
    Jonsson EN; Nyberg J
    CPT Pharmacometrics Syst Pharmacol; 2024 May; 13(5):743-758. PubMed ID: 38415822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Model-Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling.
    Bi Y; Liu J; Li L; Yu J; Bhattaram A; Bewernitz M; Li RJ; Liu C; Earp J; Ma L; Zhuang L; Yang Y; Zhang X; Zhu H; Wang Y
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S104-S111. PubMed ID: 31502691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: Building model credibility.
    Musuamba FT; Skottheim Rusten I; Lesage R; Russo G; Bursi R; Emili L; Wangorsch G; Manolis E; Karlsson KE; Kulesza A; Courcelles E; Boissel JP; Rousseau CF; Voisin EM; Alessandrello R; Curado N; Dall'ara E; Rodriguez B; Pappalardo F; Geris L
    CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):804-825. PubMed ID: 34102034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A qualitative systematic review of internal and external influences on shared decision-making in all health care settings.
    Truglio-Londrigan M; Slyer JT; Singleton JK; Worral P
    JBI Libr Syst Rev; 2012; 10(58):4633-4646. PubMed ID: 27820528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-Informed Drug Development: Current US Regulatory Practice and Future Considerations.
    Wang Y; Zhu H; Madabushi R; Liu Q; Huang SM; Zineh I
    Clin Pharmacol Ther; 2019 Apr; 105(4):899-911. PubMed ID: 30653670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Credibility assessment of computational models according to ASME V&V40: Application to the Bologna Biomechanical Computed Tomography solution.
    Aldieri A; Curreli C; Szyszko JA; La Mattina AA; Viceconti M
    Comput Methods Programs Biomed; 2023 Oct; 240():107727. PubMed ID: 37523955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacometrics meets statistics-A synergy for modern drug development.
    Ryeznik Y; Sverdlov O; Svensson EM; Montepiedra G; Hooker AC; Wong WK
    CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1134-1149. PubMed ID: 34318621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.
    Rayner CR; Smith PF; Andes D; Andrews K; Derendorf H; Friberg LE; Hanna D; Lepak A; Mills E; Polasek TM; Roberts JA; Schuck V; Shelton MJ; Wesche D; Rowland-Yeo K
    Clin Pharmacol Ther; 2021 Apr; 109(4):867-891. PubMed ID: 33555032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An AI Approach to Generating MIDD Assets Across the Drug Development Continuum.
    Barrett JS; Goyal RK; Gobburu J; Baran S; Varshney J
    AAPS J; 2023 Jul; 25(4):70. PubMed ID: 37430126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-Informed Drug Development in Pediatric Dose Selection.
    Bi Y; Liu J; Li F; Yu J; Bhattaram A; Bewernitz M; Li RJ; Ahn J; Earp J; Ma L; Zhuang L; Yang Y; Zhang X; Zhu H; Wang Y
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S60-S69. PubMed ID: 34185906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model-Informed Pediatric Drug Development: Application of Pharmacometrics to Define the Right Dose for Children.
    Vinks AA; Barrett JS
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S52-S59. PubMed ID: 34185897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is There a Need for a Dedicated Pharmacokinetic Trial for a Drug in Obese Populations? A Drug Prioritization Decision Tree Framework.
    Langevin B; Gobburu JVS; Gopalakrishnan M
    J Clin Pharmacol; 2023 Nov; 63 Suppl 2():S48-S64. PubMed ID: 37942905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacometrics and systems pharmacology for metabolic bone diseases.
    Riggs MM; Cremers S
    Br J Clin Pharmacol; 2019 Jun; 85(6):1136-1146. PubMed ID: 30690761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applications of Model-Based Meta-Analysis in Drug Development.
    Chan P; Peskov K; Song X
    Pharm Res; 2022 Aug; 39(8):1761-1777. PubMed ID: 35174432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linked Pharmacometric-Pharmacoeconomic Modeling and Simulation in Clinical Drug Development.
    Hill-McManus D; Marshall S; Liu J; Willke RJ; Hughes DA
    Clin Pharmacol Ther; 2021 Jul; 110(1):49-63. PubMed ID: 32936931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.